The Effect of CFTR Modulation on the Disease Progression of Cystic Fibrosis in the Era of Precision Medicine
Thursday, June 11, 2015 | 12:30pm
Square--Brussels Meeting Center, Copper Hall, Level 0
|J. Stuart Elborn, MD|
Professor of Respiratory Medicine
Dean, Medicine, Dentistry and Biomedical Science
Queen’s University of Belfast
Belfast, Northern Ireland, United Kingdom
|Jane Davies, MD|
Professor of Paediatric Respirology and Experimental Medicine
Imperial College London
Honorary Consultant in Paediatric Respiratory Medicine
Royal Brompton and Harefield NHSFoundation Trust
London, United Kingdom
|Scott Bell, MD|
Director, Adult Cystic Fibrosis Centre
The Prince Charles Hospital
Group Leader, Lung Bacteria Group
QIMR Berghofer Medical Research Institute
|Nico Derichs, MD|
Director, CFTR Biomarker Center and Translational CF Research Group
Senior CF Physician, Paediatric and Adult CF Center
Charité Universitätsmedizin Berlin
The expert faculty for this CME symposium will present a comprehensive review of the effects of CFTR modulation therapeutics on cystic fibrosis disease progression. The new era of precision medicine has arrived and many patients can now be managed on the basis of phenotypes where very good healthcare outcomes can be achieved. Cystic fibrosis patients on treatment show new progress on lung function, BMI, exercise ability, infectious complications, life expectancy, co-morbid conditions such as diabetes, liver failure, bone disease, and overall quality of life. This clinically relevant symposium also includes interactive panel discussions with case presentations to advance your skills in caring for cystic fibrosis patients.
- Review the principles of precision medicine as it pertains to CFTR modulation therapeutics.
- Recognize risk factors and predictors of disease progression in the cystic fibrosis patient.
- Evaluate the impact of CFTR modulation therapeutics on disease progression in the patient with cystic fibrosis.
- Describe current approaches to effectively manage patients on CFTR modulation therapeutics.
|12:30-12:40||Welcome and Introduction: The Rationale for Applying the Principles of Precision Medicine in the New Era of Therapeutic CFTR Modulation||J. Stuart Elborn, MD|
|12:40-12:55||Characterizing and Predicting Disease Progression in Patients with Cystic Fibrosis||Jane Davies, MD|
|12:55-13:05||Case Presentation with Interactive Panel Discussion|
|13:05-13:20||Review of the Data for the Effects of Therapeutic CFTR Modulation on Disease Progression||Scott Bell, MD|
|13:20-13:30||Case Presentation with Interactive Panel Discussion|
|13:30-13:45||Evaluating the Impact of CFTR Modulation Therapeutics on Patients with Cystic Fibrosis||Nico Derichs, MD|
|13:45–14:00||Panel Discussion and Conclusion|
Pulmonologists, pediatricians, infectious disease, and other healthcare clinicians responsible for the care of patients with cystic fibrosis.
This activity has been accredited by the European Board for Accreditation in Pneumology (EBAP) for 1 European Continuing Medical Education (CME) credit.
The "Elsevier Office of Continuing Medical Education" (or) "The Effect of CFTR Modulation on the Disease Progression of Cystic Fibrosis in the Era of Precision Medicine" is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.
The "The Effect of CFTR Modulation on the Disease Progression of Cystic Fibrosis in the Era of Precision Medicine" is designated for a maximum of (or "for up to") 1 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.
Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.
Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. The EACCME credit system is based on 1 ECMEC per hour with a maximum of 3 ECMECs for half a day and 6 ECMECs for a full-day event.
There is no registration fee for attending this symposium; however, seating is limited. Preregistration does not guarantee seating. We recommend arriving at the symposium location early.
This symposium supported by an educational grant from Vertex Pharmaceuticals Incorporated.
Co-sponsored by Elsevier Office of Continuing Medical Education and AcademicCME